ACRV Stock — Acrivon Therapeutics, Inc. Common Stock

Acrivon Therapeutics, Inc. Common Stock (ACRV)

Updated October 16, 2026.

ACRV is a Stock. Total return is -90.1% over the past 3.9 years, 191.8 points behind SPY at 101.7%.

Acrivon Therapeutics is a clinical-stage biopharmaceutical company developing oncology medicines paired with companion diagnostics through its generative phosphoproteomics platform. The company's lead candidate, ACR-368, is a selective inhibitor targeting cell cycle checkpoints for endometrial cancer, platinum-resistant ovarian cancer, and squamous cell cancers, with additional programs in development. This is an early-stage biotech company with no established distribution history, making it oriented toward investors seeking exposure to cancer drug development rather than current income.

ACRV performance versus SPY

Price and return data through 2026-10-16.

Total return is -90.1% over the past 3.9 years, 191.8 points behind SPY at 101.7%. Over the past year its total return — price change plus distributions reinvested — is -12.3%. Its deepest 1-year drawdown was 57.1%.

ACRV key facts

Asset type

Stock

Asset class

Equity

Inception date

11/15/2022

Distribution frequency

None

Last close

$1.64 (as of 2026-10-16)

Market cap

$70,279,514

Average volume

261578.0

Beta

1.925

Payout ratio

0.0%

EPS

$-1.88

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ACRV risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 57.1%.

Who may consider ACRV — and who may not

It is a weaker fit for investors who need monthly cash flow (ACRV does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on ACRV

• All tickers starting with A

Tagged: Healthcare.

Frequently asked questions